{"nctId":"NCT01028027","briefTitle":"Loteprednol and Tobramycin Versus Tobramycin and Dexamethasone, in the Treatment of Blepharokeratoconjunctivitis","startDateStruct":{"date":"2009-10"},"conditions":["Conjunctivitis","Keratitis","Blepharitis"],"count":357,"armGroups":[{"label":"Loteprednol and tobramycin","type":"EXPERIMENTAL","interventionNames":["Drug: Loteprednol and tobramycin"]},{"label":"Tobramycin and dexamethasone","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Tobramycin and dexamethasone"]}],"interventions":[{"name":"Loteprednol and tobramycin","otherNames":["Zylet"]},{"name":"Tobramycin and dexamethasone","otherNames":["Tobradex"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects must have a clinical diagnosis of BKC in at least one eye\n* Subjects must be willing to discontinue contact lens use for the duration of the study\n* Subjects who are able and willing to comply with all treatment and follow- up/study procedures.\n\nExclusion Criteria:\n\n* Subjects participating in any drug or device clinical investigation within 30 days prior to entry into this study and/or during the period of study participation.\n* Subjects who have any uncontrolled systemic disease or debilitating disease.\n* Subjects who have a known hypersensitivity to the study drugs or their components (including benzalkonium chloride) or contraindications to tobramycin or ocular corticosteroids.\n* Subjects who use any topical or systemic ophthalmic medications listed as disallowed in the study protocol, within the specified time frame prior to Visit 1.\n* Subjects who have a disease or conditions which the Investigator determines could interfere with the safety and efficacy evaluations of the study drug.\n* Subjects having ocular surgery (including laser surgery) in either eye within the past three months.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Signs and Symptoms Composite Score - Change From Baseline to Day 15 - PP Population","description":"The change from baseline (CFB) to Day 15 (Visit 4) in the ocular signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. Per protocol population (PP).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.63","spread":"4.56"},{"groupId":"OG001","value":"-12.41","spread":"4.71"}]}]}]},{"type":"SECONDARY","title":"Signs and Symptoms Composite Score - Change From Baseline to Day 15 - ITT Population","description":"The CFB to Day 15 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.64","spread":"4.55"},{"groupId":"OG001","value":"-11.98","spread":"4.95"}]}]}]},{"type":"SECONDARY","title":"Signs and Symptoms Composite Score - Change From Baseline to Day 8 - PP Population","description":"The CFB to Day 8 (Visit 3) in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.20","spread":"3.94"},{"groupId":"OG001","value":"-10.21","spread":"4.23"}]}]}]},{"type":"SECONDARY","title":"Signs and Symptoms Composite Score - Change From Baseline to Day 8 - ITT Population","description":"The CFB to Day 8 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.91","spread":"4.24"},{"groupId":"OG001","value":"-9.96","spread":"4.27"}]}]}]},{"type":"SECONDARY","title":"Signs and Symptoms Composite Score Change From Baseline to Day 3 - PP Population","description":"The CFB to Day 3 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. PP population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.66","spread":"3.46"},{"groupId":"OG001","value":"-5.98","spread":"3.68"}]}]}]},{"type":"SECONDARY","title":"Signs and Symptoms Composite Score Change From Baseline to Day 3 - ITT Population","description":"The CFB to Day 3 in the signs and symptoms composite score. Ocular signs and symptoms were collected for study eyes at each study visit using a 0-4 grading scale, assessed as 0 = none, 1 = minimal/trace, 2 = mild, 3 = moderate, and 4 = severe. The signs and symptoms composite score was the sum of each individual sign or symptom score. ITT population.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.54","spread":"3.48"},{"groupId":"OG001","value":"-5.92","spread":"3.69"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":177},"commonTop":["Increased IOP"]}}}